With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

A Phase 1 trial that is testing Modex's vaccine against the Epstein-Barr virus, a strong risk factor for MS, has dosed its ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments ...

GSK, Pfizer, Johnson & Johnson, Reynolds American, Novartis, Imperial Brands, Cipla Limited, British American Tobacco, Merck ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

The recipient in Changsha, the capital of Hunan province, became the first man on the Chinese mainland to receive the HPV ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...